Efficacy and safety of tanezumab added on to diclofenac sustained release in patients with knee or hip osteoarthritis: A double-blind, placebo-controlled, parallel-group, multicentre phase III randomised clinical trial

Annals of the Rheumatic Diseases

Volumn 73, Issue 9, 2014, Pages 1665-1672

  Balanescu, Andra Rodica ^a   Feist, Eugen ^b   Wolfram, Gernot ^c   Davignon, Isabelle ^c   Smith, Michael D ^c   Brown, Mark T ^c   West, Christine R ^c  

^a CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTHRITIS; KNEE OSTEOARTHRITIS; OSTEOARTHRITIS;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL, HUMANIZED; DELAYED-ACTION PREPARATIONS; DICLOFENAC; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEOARTHRITIS, HIP; OSTEOARTHRITIS, KNEE; PAIN; PAIN MEASUREMENT; RECEPTOR, NERVE GROWTH FACTOR; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84905193109     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2012-203164     Document Type: Article

References (27)

1. Leardini G, Salaffi F, Caporali R, et al. Direct and indirect costs of osteoarthritis of the knee. Clin Exp Rheumatol 2004;22:699-706. (Pubitemid 40045531)
2. Woolf AD, Pfleger B. Burden of major musculoskeletal conditions. Bull World Health Organ 2003;81:646-56. (Pubitemid 37254686)
3. Jordan KM, Arden NK, Doherty M, et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003;62:1145-55. (Pubitemid 37500619)
4. Zhang W, Doherty M, Arden N, et al. EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2005;64:669-81. (Pubitemid 40559291)
5. Zhang W, Moskowitz RW, Nuki G, et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 2008;16:137-62. (Pubitemid 351222155)
6. Abdiche YN, Malashock DS, Pons J. Probing the binding mechanism and affinity of tanezumab, a recombinant humanized anti-NGF monoclonal antibody, using a repertoire of biosensors. Protein Sci 2008;17:1326-35.
7. Hefti FF, Rosenthal A, Walicke PA, et al. Novel class of pain drugs based on antagonism of NGF. Trends Pharmacol Sci 2006;27:85-91. (Pubitemid 43184029)
8. Evans RJ, Moldwin RM, Cossons N, et al. Proof of concept trial of tanezumab for the treatment of symptoms associated with interstitial cystitis. J Urol 2011;185:1716-21.
9. Katz N, Borenstein DG, Birbara C, et al. Efficacy and safety of tanezumab in the treatment of chronic low back pain. Pain 2011;152:2248-58.
10. Lane NE, Schnitzer TJ, Birbara CA, et al. Tanezumab for the treatment of pain from osteoarthritis of the knee. N Engl J Med 2010;363:1521-31.
11. Nagashima H, Suzuki M, Araki S, et al. Preliminary assessment of the safety and efficacy of tanezumab in Japanese patients with moderate to severe osteoarthritis of the knee: a randomized, double-blind, dose-escalation, placebo-controlled study. Osteoarthritis Cartilage 2011;19:1405-12.
12. Schnitzer TJ, Lane NE, Birbara C, et al. Long-term open-label study of tanezumab for moderate to severe osteoarthritic knee pain. Osteoarthritis Cartilage 2011;19:639-46.
13. Altman R, Asch E, Bloch D, et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum 1986;29:1039-49.
14. Kellgren JH, Lawrence JS. Radiological assessment of osteo-arthrosis. Ann Rheum Dis 1957;16:494-502.
15. Bellamy N, Buchanan WW, Goldsmith CH, et al. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 1988;15:1833-40. (Pubitemid 19037656)
16. Stengaard-Pedersen K, Ekesbo R, Karvonen AL, et al. Celecoxib 200 mg q.d. is efficacious in the management of osteoarthritis of the knee or hip regardless of the time of dosing. Rheumatology (Oxford) 2004;43:592-5. (Pubitemid 38628189)
17. Pham T, van der Heijde D, Altman RD, et al. OMERACT-OARSI initiative: Osteoarthritis Research Society International set of responder criteria for osteoarthritis clinical trials revisited. Osteoarthritis Cartilage 2004;12:389-99. (Pubitemid 38594267)
18. Watson JJ, Allen SJ, Dawbarn D. Targeting nerve growth factor in pain: what is the therapeutic potential? BioDrugs 2008;22:349-59.
19. Brown MT, Murphy FT, Radin DM, et al. Tanezumab reduces osteoarthritic hip pain: Results of a randomized, double-blind, placebo-controlled phase 3 trial. Arthritis Rheum 2013;65:1795-1803.
20. Brown MT, Murphy FT, Radin DM, et al. Tanezumab reduces osteoarthritic knee pain: results of a randomized, double-blind, placebo-controlled phase III trial. J Pain 2012;13:790-8.
21. Ekman EF, Gimbel JS, Bello AE, et al. Efficacy and safety of intravenous tanezumab in osteoarthritis hip and knee pain: comparison to placebo and naproxen in two phase III studies (NCT00830063 & NCT00863304). Presented at The American Pain Society (APS) 30th Annual Scientific Meeting; 19-21 May 2011, Austin, TX.
22. Yazici Y, Ekman EF, Greenberg HS, et al. Efficacy of tanezumab compared with non-steroidal anti-inflammatory drugs in patients with knee or hip osteoarthritis (NCT00809354). Presented at the American College of Rheumatology (ACR)/Association of Rheumatology Health Professionals (ARHP) Annual Scientific Meeting; 5-9 November 2011 Chicago, IL.
23. Farrar JT, Young JP Jr, LaMoreaux L, et al. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 2001;94:149-58. (Pubitemid 33016608)
24. Rowbotham MC. What is a 'clinically meaningful' reduction in pain? Pain 2001;94:131-2. (Pubitemid 33016605)
25. Pfizer Inc. Tanezumab Arthritis Advisory Committee Briefing Document. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/ Drugs/ArthritisDrugsAdvisoryCommittee/UCM295205.pdf (accessed 10 Apr 2012).
26. Food and Drug Administration Center for Drug Evaluation and Research. Background Materials. Meeting of the Arthritis Advisory Committee (AAC). http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/ Drugs/ArthritisDrugsAdvisoryCommittee/UCM295202.pdf (accessed 10 Apr 2012).
27. Food and Drug Administration Center for Drug Evaluation and Research. Background Materials Addendum. http://www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/ArthritisDrugsAdvisoryCommittee/UCM295203.pdf (accessed 10 Apr 2012).